We are live on ! Find out more
SCM

Superstring Capital Management Portfolio holdings

AUM $140M
1-Year Est. Return 323.19%
This Fund
S&P 500
This Quarter Est. Return
-20.91%
1 Year Est. Return
+323.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$79.3M
AUM Growth
-$71.9M
Cap. Flow
-$39.4M
Cap. Flow %
-49.61%
Top 10 Hldgs %
66.81%
Holding
58
New
21
Increased
4
Reduced
13
Closed
19

Top Buys

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$7.13M
2
TERN
Terns Pharmaceuticals
TERN
+$5.79M
3
ZLAB icon
Zai Lab
ZLAB
+$3.78M
4
ACLX
Arcellx
ACLX
+$3.21M
5
ARWR icon
Arrowhead Research
ARWR
+$2.73M

Top Sells

Rank Stock Value
1
IDYA icon
IDEAYA Biosciences
IDYA
+$9.53M
2
SVRA icon
Savara
SVRA
+$8.3M
3
DAWN
Day One Biopharmaceuticals
DAWN
+$5.78M
4
ROIV icon
Roivant Sciences
ROIV
+$5.6M
5
CYTK icon
Cytokinetics
CYTK
+$5.51M

Sector Composition

Rank Sector Weight
1 Healthcare 99.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
1
Cytokinetics
CYTK
$10.9B
$10.2M 12.82%
187,633
-91,282
-33% -$5.51M
LEGN icon
2
Legend Biotech
LEGN
$4.31B
$6.85M 8.64%
+154,665
New +$7.13M
TERN
3
DELISTED
Terns Pharmaceuticals
TERN
$6.51M 8.21%
+956,542
New +$5.79M
BBIO icon
4
BridgeBio Pharma
BBIO
$15.9B
$5.57M 7.02%
219,837
-133,670
-38% -$3.65M
ETNB
5
DELISTED
89bio
ETNB
$5.45M 6.87%
680,403
-260,884
-28% -$2.33M
NKTX icon
6
Nkarta
NKTX
$186M
$5.18M 6.53%
875,999
-313,194
-26% -$2.22M
ZLAB icon
7
Zai Lab
ZLAB
$2.28B
$3.73M 4.7%
+215,178
New +$3.78M
KROS icon
8
Keros Therapeutics
KROS
$211M
$3.39M 4.28%
74,288
+40,460
+120% +$2.17M
ACLX
9
DELISTED
Arcellx
ACLX
$3.26M 4.11%
+59,133
New +$3.21M
ARWR icon
10
Arrowhead Research
ARWR
$10.5B
$2.89M 3.64%
+111,133
New +$2.73M
CRBP icon
11
Corbus Pharmaceuticals
CRBP
$167M
$2.56M 3.22%
+56,468
New +$2.38M
ONC
12
BeOne Medicines Ltd
ONC
$32.4B
$1.78M 2.25%
+12,508
New +$1.93M
FATE icon
13
Fate Therapeutics
FATE
$324M
$1.63M 2.06%
497,360
-423,116
-46% -$1.85M
ALLO icon
14
Allogene Therapeutics
ALLO
$618M
$1.61M 2.03%
689,912
+168,663
+32% +$498K
PYXS icon
15
Pyxis Oncology
PYXS
$150M
$1.6M 2.02%
484,443
-9,316
-2% -$39.2K
APGE icon
16
Apogee Therapeutics
APGE
$10.1B
$1.45M 1.83%
36,928
-7,940
-18% -$385K
CTMX icon
17
CytomX Therapeutics
CTMX
$788M
$1.4M 1.77%
1,151,518
+472,115
+69% +$940K
NAMS icon
18
NewAmsterdam Pharma
NAMS
$3.7B
$1.23M 1.56%
+64,213
New +$1.29M
TRML
19
DELISTED
Tourmaline Bio
TRML
$1.22M 1.54%
95,229
+25,257
+36% +$406K
NVCR icon
20
NovoCure
NVCR
$1.84B
$1.15M 1.44%
+66,892
New +$1.18M
SYRE icon
21
Spyre Therapeutics
SYRE
$8.7B
$1.07M 1.35%
+45,571
New +$1.54M
CABA icon
22
Cabaletta Bio
CABA
$461M
$1.05M 1.32%
139,895
-150,902
-52% -$1.85M
TNGX icon
23
Tango Therapeutics
TNGX
$4.65B
$992K 1.25%
+115,571
New +$893K
ALLK
24
DELISTED
Allakos
ALLK
$941K 1.19%
940,578
-293,161
-24% -$348K
CATX icon
25
Perspective Therapeutics
CATX
$341M
$874K 1.1%
+87,638
New +$1.27M
1
2 3

Similar funds

GIM
Guild Investment Management Los Angeles, California $140M AUM 28.67% 1-Year Est. Return
SLWM
Stone Loft Wealth Management West Chester, Pennsylvania $140M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $140M AUM
WCM
WealthTrak Capital Management Virginia Beach, Virginia $140M AUM 17% 1-Year Est. Return
JD6
J Digital 6 Chicago, Illinois $140M AUM
CPC
CFC Planning Company Cicero, Indiana $140M AUM 22.33% 1-Year Est. Return
CFG
Chapman Financial Group Kailua, Hawaii $140M AUM 15.83% 1-Year Est. Return
RC
Rexford Capital Bellaire, Texas $140M AUM 28.19% 1-Year Est. Return

Superstring Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Superstring Capital Management held 58 positions worth $79.3M, down 48% from $151M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Superstring Capital Management withdrew a net $39.4M in Q2 2024, closing 19 positions and reducing 13 holdings. Its most notable exit was IDEAYA Biosciences, an estimated $9.53M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier.

Against the trend, Superstring Capital Management opened a new position in Legend Biotech worth $6.85M.

  • Superstring Capital Management's largest Q2 2024 buy was Legend Biotech: 154,665 shares worth $6.85M.
  • Superstring Capital Management added most to Keros Therapeutics in Q2 2024, an estimated $2.17M increase.
  • Superstring Capital Management's biggest Q2 2024 reduction was Savara, cutting an estimated $8.3M.
  • Superstring Capital Management fully exited IDEAYA Biosciences in Q2 2024, selling an estimated $9.53M.
  • Superstring Capital Management's ten largest holdings make up 67% of its $79.3M portfolio in Q2 2024.
  • Superstring Capital Management opened 21 new positions and closed 19 in Q2 2024.
  • Superstring Capital Management's portfolio value fell 48% quarter-over-quarter to $79.3M.

Based on Superstring Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.